Xenetic Biosciences
XBIO
9 hedge funds and large institutions have $797K invested in Xenetic Biosciences in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
14% more capital invested
Capital invested by funds: $699K → $797K (+$98.4K)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
18% less funds holding
Funds holding: 11 → 9 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.9K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$8.32K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$489 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 2 |
Bank of New York Mellon
New York
|
-$21K |
| 3 |
Barclays
London,
United Kingdom
|
-$3.18K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $628K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $90K | +$489 | +2 | +0.5% |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $35K | +$15.9K | +65 | +76% |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $32K | +$8.32K | +34 | +33% |
|
5
Morgan Stanley
New York
| $6K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | -$1.22K | -5 | -29% |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $2.47K | – | – | – |
|
|
OIA
8
OneDigital Investment Advisors
Overland Park,
Kansas
| $1K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$22K | -115 | Closed |
|
|
10
Bank of New York Mellon
New York
| – | -$21K | -108 | Closed |
|
|
11
Barclays
London,
United Kingdom
| – | -$3.18K | -13 | -87% |
|
XBIO Hedge Fund Activity: Q1 2019 in Review
9 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2019, worth a combined $797K — up 14% from $699K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XBIO and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Acadian Asset Management, adding an estimated $15.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $22K sold.
- 9 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2019, down from 11 in Q4 2018.
- Funds reported $797K of Xenetic Biosciences stock for Q1 2019, up 14% quarter-over-quarter.
- 0 funds opened new Xenetic Biosciences positions in Q1 2019 and 2 closed out, a net change of -2 holders.
- The largest Xenetic Biosciences buyer in Q1 2019 was Acadian Asset Management, an estimated $15.9K added.
- The largest Xenetic Biosciences seller in Q1 2019 was Citadel Advisors, an estimated $22K sold.
Based on aggregated 13F filings for Q1 2019.